Shaanxi Panlong Pharmaceutical Group Co., Ltd. (SHE:002864)

SHE:002864 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Revenue Revenue Growth	1,113	1,141	973.86	980.83	974.29	887.48
Revenue Growth	9.79%	17.15%	-0.71%	0.67%	9.78%	32.40%
Gross Profit Gross Profit Growth	578.81	591.62	592.12	567.09	566.04	517.12
Operating Income Operating Income Growth	87.01	86.81	106.53	113.11	113.1	103.05
Net Income Net Income Growth	86.79	96.28	120.27	110.43	101.16	93.17
Earnings Per Share EPS Growth	0.64	0.71	0.88	0.87	0.90	0.84
EPS Growth	-27.80%	-20.00%	1.77%	-3.42%	7.33%	18.48%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Self-Produced Chinese Patent Medicine Self-Produced Chinese Patent Medicine Growth	644.11	644.93	585.22	555.5	508.13
Chinese Herbal Pieces Chinese Herbal Pieces Growth	235	91.27	23.23	20.54	23.76
Pharmaceutical Commercial Distribution Pharmaceutical Commercial Distribution Growth	254.08	231.27	365.48	389.47	347.3
Health Products Health Products Growth	2.14	0.96	3.72	5.45	4.56
Other Other Growth	5.53	5.42	3.17	3.34	-
Total Total Growth	1,141	973.86	980.83	974.29	887.48

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Investments Cash & Investments Growth	1,230	1,095	1,169	1,102	823.44	419.3
Total Debt Total Debt Growth	152.35	100.83	152.14	102.49	427.16	143.9
Net Cash (Debt) Net Cash Growth	1,078	994.06	1,017	999.52	396.28	275.41
Net Cash Growth	6.24%	-2.28%	1.77%	152.22%	43.89%	-1.78%
Net Cash Per Share Net Cash Per Share Growth	7.93	7.31	7.48	7.87	3.53	2.48

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Operating Cash Flow Operating Cash Flow Growth	130.05	63.01	156.59	104.05	125.36	116.04
Capital Expenditures CapEx Growth	-28.46	-42.41	-82.05	-62.51	-55.84	-80.68
Free Cash Flow Free Cash Flow Growth	101.59	20.6	74.54	41.53	69.53	35.36
Free Cash Flow Growth	154.08%	-72.36%	79.47%	-40.26%	96.63%	67.91%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Gross Margin	52.00%	51.86%	60.80%	57.82%	58.10%	58.27%
Operating Margin	7.82%	7.61%	10.94%	11.53%	11.61%	11.61%
Pretax Margin	9.55%	9.55%	14.06%	13.18%	12.23%	12.29%
Profit Margin	7.80%	8.44%	12.35%	11.26%	10.38%	10.50%
FCF Margin	9.13%	1.81%	7.65%	4.23%	7.14%	3.98%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Dividend Per Share Dividend Per Share Growth	0.269	0.269	0.192	0.169	0.154	0.139
Dividend Per Share Growth	-18.75%	39.99%	13.65%	10.01%	11.05%	20.02%
Dividend Yield	1.30%	1.15%	0.84%	0.59%	0.53%	0.60%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
PE Ratio	31.70	33.92	26.59	36.65	32.81	28.77
Forward PE	-	16.47	16.47	21.22	74.31	74.31
P/FCF Ratio	27.44	158.52	42.90	97.45	47.73	75.80
PS Ratio	2.50	2.86	3.28	4.13	3.41	3.02

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error